CClinicalTrials.gg
Status unknownNCT02883088CLIMAUpdated Dec 21, 2017

Relationship Between OCT Coronary Plaque Morphology and Clinical Outcome

An observational study in Coronary Artery Disease, sponsored by San Giovanni Addolorata Hospital. Status unknown at 14 sites in 3 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-12-21.

Sponsored by San Giovanni Addolorata Hospital · Observational

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,003
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The multicenter observational CLIMA registry has been conceived to explore correlation between OCT morphology of atherosclerotic plaques located in the left anterior descending artery with mid and long term clinical outcome.

Read the detailed description

Acute myocardial infarction (MI) is commonly caused by plaque ulceration and subsequent local thrombosis. Plaques that tend to rupture are typically characterized by a large superficial lipid pool, delimited by a thin fibrous cap and often exhibit local signs of inflammation. Such atherosclerotic lesions are commonly described as vulnerable plaques (1-4).

Identification of these plaque features with imaging modalities is potentially a valid approach to identify patients at increased risk of M (5). Optical coherence tomography is capable of visualizing superficial plaque components at a high resolution (in the range of 10-15 microns) and can depict all the features of plaque vulnerability or thrombogenicity (6,7).

The aim of the study is to relate presence of multiple OCT criteria of plaque vulnerability with following clinical events in a subset of coronary lesions. For this purpose all plaques in the proximal-mid portion of the left anterior descending artery will be evaluated with FD-OCT assessing the following criteria:

  • minimum lumen area (MLA) \<3.5 mm2:
  • fibrous cap minimum thickness \<75 µm:
  • lipid arc extension >180°;
  • presence of macrophages;
02

Conditions studied

  • Coronary Artery Disease

Keywords

  • Optical coherence tomograhpy
  • registry
  • Coronary artery disease
03

In context

Coronary Artery Disease

5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.

This study's enrollment of 1,003 is above the median of 336 across 1,947 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

San Giovanni Addolorata Hospital is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All consecutive subjects undergoing OCT assessment of the proximal left descending artery coronary during coronary angiography should be screened for eligibility.

Patients will be enrolled from participating centers at the time of OCT assessment and prospectively investigated to evaluate clinical outcome.

Inclusion criteria

  • Age >18 years;
  • Patients with clinical indication to coronary angiography undergoing OCT evaluation of the left anterior descending artery regardless of the clinical syndrome;
  • Patients with at least 30 mm of naïve OCT-assessable proximal-mid left anterior descending artery;
  • Patient has been informed of the nature of the study and agrees to its provisions and has provided written informed consent to the procedure;

Exclusion criteria

Exclusion Criteria:

  • Female with childbearing potential or lactating;
  • Acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl);
  • Advanced heart failure (NYHA III-IV)
  • Previous Coronary artery by-pass surgery
  • Previous stenting of proximal-mid left anterior descending artery with residual untreated segment \<30mm.
  • Co-morbidities that could interfere with completion of study procedures, or life expectancy less than 1 year;
  • Participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study;
  • Heavily calcified vessel and/or lesion which cannot be successfully imaged by OCT
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,003 participants (actual)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • LAD-group

    Subjects over 18 years who are undergoing Frequency Domain - Optical Coherence Tomography (FD-OCT) evaluation of the native left anterior descending artery during clinically indicated coronary angiography regardless of the clinical syndrome (silent ischemia, effort angina or acute coronary syndrome).

    Procedure: Frequency Domain - Optical Coherence Tomography (FD-OCT)

Interventions

  • ProcedureFrequency Domain - Optical Coherence Tomography (FD-OCT)

    FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography

06

What researchers measure

Primary outcomes

  1. Major adverse cardiac events

    Composite of cardiac death and/or target vessel myocadial infarction

    Time frame: 1-year

Secondary outcomes

  1. Major adverse cardiac events

    Composite of cardiac death and/or target vessel myocadial infarction

    Time frame: 3-year

Other outcomes

  1. Predictive value of single OCT criteria of plaque vulnerability

    Predictive value of minimum lumen area, fibrous cap thickness, lipid arc extension, presence of macrophages at the explored plaques

    Time frame: 1-year and 3-year

07

Study locations

14 sites
  • Policlinico Sant'Orsola-Malpighi
    Bologna, Italy
  • Ospedale Brotzu
    Cagliari, Italy
  • Presidio Ospedaliero Sant'Elia
    Caltanissetta, Italy
  • University of Catania
    Catania, Italy
  • GVM Care and Research, E. S. Health Science Foundation
    Cotignola, Italy
  • Misericordia Hospital
    Grosseto, Italy
  • Ospedale Civile Ferdinando Veneziale
    Isernia, Italy
  • Policlinico G. Martino
    Messina, Italy
  • Centro Cardiologico Monzino IRCCS
    Milano, Italy
  • San Giovanni-Addolorata Hospital
    Rome, Italy
  • Università Cattolica Del Sacro Cuore
    Rome, Italy
  • Presidio Ospedaliero Umberto I°
    Siracusa, Italy
  • Central Clinical Hospital of the Ministry of Interior
    Warsaw, Poland
  • Hospital Universitario Clinico San Carlos
    Madrid, Spain
08

References and documents

Publications

  • Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995 Aug 1;92(3):657-71. doi: 10.1161/01.cir.92.3.657. No abstract available. PubMed 7634481 ↗
  • De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Clin Nutr Metab Care. 2000 Nov;3(6):453-67. doi: 10.1097/00075197-200011000-00007. PubMed 11085831 ↗
  • Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003 Oct 7;108(14):1664-72. doi: 10.1161/01.CIR.0000087480.94275.97. PubMed 14530185 ↗
  • Narula J, Nakano M, Virmani R, Kolodgie FD, Petersen R, Newcomb R, Malik S, Fuster V, Finn AV. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol. 2013 Mar 12;61(10):1041-51. doi: 10.1016/j.jacc.2012.10.054. PubMed 23473409 ↗
  • Jang IK, Bouma BE, Kang DH, Park SJ, Park SW, Seung KB, Choi KB, Shishkov M, Schlendorf K, Pomerantsev E, Houser SL, Aretz HT, Tearney GJ. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. J Am Coll Cardiol. 2002 Feb 20;39(4):604-9. doi: 10.1016/s0735-1097(01)01799-5. PubMed 11849858 ↗
  • Jang IK, Tearney GJ, MacNeill B, Takano M, Moselewski F, Iftima N, Shishkov M, Houser S, Aretz HT, Halpern EF, Bouma BE. In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation. 2005 Mar 29;111(12):1551-5. doi: 10.1161/01.CIR.0000159354.43778.69. Epub 2005 Mar 21. PubMed 15781733 ↗
  • Kawasaki M, Bouma BE, Bressner J, Houser SL, Nadkarni SK, MacNeill BD, Jang IK, Fujiwara H, Tearney GJ. Diagnostic accuracy of optical coherence tomography and integrated backscatter intravascular ultrasound images for tissue characterization of human coronary plaques. J Am Coll Cardiol. 2006 Jul 4;48(1):81-8. doi: 10.1016/j.jacc.2006.02.062. Epub 2006 Jun 9. PubMed 16814652 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02883088
Lead sponsor
San Giovanni Addolorata Hospital
Collaborators
Centro per la Lotta Contro l'Infarto - Fondazione Onlus
Responsible party
Francesco Prati (Dr., San Giovanni Addolorata Hospital) — Principal investigator
First posted
Aug 30, 2016
Start date
Jan 1, 2013
Primary completion
Dec 1, 2016
Completion
Dec 1, 2019 (estimated)
Last update
Dec 21, 2017

Study contacts

Francesco Prati, MD
principal investigator · San Giovanni Addolorata Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion